Please login to the form below

Not currently logged in
Email:
Password:

neratinib

This page shows the latest neratinib news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s leukaemia drug Mylotarg backed for use in EU

Pfizer’s leukaemia drug Mylotarg backed for use in EU

There was worse news for Puma Biotechnology - which has its application to market Nerlyx (neratinib) for breast cancer turned down - and also Pfizer whose application to extend the indications of Sutent

Latest news

  • Roche trumpets APHINITY data, but did it hit the mark? Roche trumpets APHINITY data, but did it hit the mark?

    The results of the APHINITY trial could present an opportunity to US biotech Puma, which won a positive recommendation from an FDA advisory committee for its neratinib candidate in post-surgery ... In trials, neratinib achieved a 33% reduction in the

  • FDA panel backs Puma's breast cancer drug, with reservations FDA panel backs Puma's breast cancer drug, with reservations

    US biotech Puma took a step closer to approval of its breast cancer therapy neratinib after an FDA advisory committee voted in favour of the drug. ... A number of analysts have suggested neratinib may be approved only in patients with hormone

  • Oncology bias in pharma deals

    Pfizer has licensed the worldwide commercial rights of Neratinib, a phase II pan-HER inhibitor (potent irreversible tyrosine kinase inhibitor) in the neoadjuvant, adjuvant and advanced settings in HER2/ErbB2 positive ... 2 ##. Pfizer/Puma Biotechnology ##

  • Never-ending story: modernising clinical trial design

    I-SPY 2 has already brought together compounds from Pfizer (neratinib), Abbott Laboratories (ABT-888) and Takeda Pharmaceutical Industries (AMT-386), and there appears to be an almost unprecedented level of

  • Multi-pronged approach

    HER2 inhibitor neratinib (Pfizer) and the PARP inhibitor veliparib (Abbott Laboratories).

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Anthill is a specialist digital agency and a strategic partner for life science companies....

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics